Skip to the guide Know the rule before the visit. Browse Georgia rules Menu Home Georgia rules License checks Online visits Compounding Care costs Drug approval Care concerns Georgia Peptide Clinic Georgia rules, mapped subject by subject. Takes on no cases. Sources Georgia rules Check a license What a treatment claim can establish An offer says a preparation is “registered” or uses an official-looking number. Pause on the exact word. A record can establish something useful without establishing drug approval. An entry in the National Drug Code Directory gives a product an identifying code, called an NDC. FDA—the Food and Drug Administration—distinguishes a directory entry from drug approval. FDA registration of a place that makes medicines is separate from FDA approval of the medicines. Match a claim to the product, the form and the source that supports it. Federal records and approval distinctions on this page were checked November 3, 2026. Read the claim before the badge Suppose a care page points to a government directory. Ask which entry it means and what that entry records. Keep the wording of the claim beside the source. Look for a direct answer rather than a link to a general home page. FDA says a National Drug Code listing does not mean it has verified the listing or approved the product. The company listing the product provides its information. An office or other care provider does not receive FDA approval. That distinction helps separate the professional-license question from the medicine question. Use Georgia’s board searches for the person and pharmacy. Use a drug approval record to check a claim about the medicine. Approval belongs to a particular product A federal approval record applies to a particular medicine and use; “peptide therapy” itself is not an approval category. The November 3, 2026 federal check includes approved tirzepatide products, Mounjaro and Zepbound, and approved semaglutide products, Ozempic and Wegovy. That fact does not turn a compounded preparation with the same ingredient name into an approved product. Compounded medicines have not had FDA review of safety, effectiveness and quality before sale. Ask for the exact generic name, product name and form. Keep both the ingredient name and any brand name in your notes. Then ask what the source says about that product’s use. A different form or preparation needs its own answer. A compounded version is not an approved generic simply because a sales page calls it a generic. FDA lists that description among misleading compounding claims. Separate a finding from a decision A reference to a committee can sound like a final agency decision. Read who made the statement and what happened next. The date belongs with the claim. In the October 30, 2026 draft, the U.S. Department of Health and Human Services (HHS) reports committee support for semax, epitalon, KPV, MOTS-c, BPC-157 and TB-500. A committee vote remains advice. It does not itself amend the official 503A ingredient list or provide FDA approval. The draft describes a plan to refrain from enforcement for listed preparations made with a single ingredient, if its conditions are met. It does not cover blends or create a general right to compound. Take that distinction to any offer relying on the committee’s meeting. Ask how the exact preparation fits the published policy, and read the separate compounding page for its scope. What a problem report means A problem that happens while a person uses a medical product is called an adverse event. Reporting the event does not prove that the product was its cause. The reports cannot tell you how often medicine users have a particular problem, FDA cautions. A reported account may also lack medical confirmation. If someone cites a count to make an offer sound reassuring or frightening, ask what the count includes and what it cannot show. Keep the source’s stated limits beside the number. Do not let a headline do more work than the source. Make the source useful at the visit Bring a short note with the exact claim, a link to the source and your open question. Ask how the evidence relates to the treatment actually being discussed. Ask what remains uncertain and what would lead the prescriber to choose another approach. The aim is a clearer conversation about your care. It is fine to ask for an unfamiliar word to be restated or for a source to be opened together. Leave with the part you understand and the part still awaiting an answer. Sources for this page Approval and legal-status check: November 3, 2026. Reporting definitions were checked September 17, 2026. FDA National Drug Code Directory limits FDA on what approval means FDA compounding distinctions HHS draft policy and account of the vote FDA adverse-event dashboard limits Keep the next question in view. Check the preparation’s rules Georgia Peptide Clinic A reading guide to Georgia peptide care, with no care offered and nothing sold. All rules and questions Home Georgia rules License checks Online visits Compounding Care costs Drug approval Care concerns © Georgia Peptide Clinic. Read this page as text Back to the page